We have designed our platform to provide higher sensitivity in detection of genetic abnormalities enabling us to provide more accurate and reliable results.
PGT is a genetic test used to analyze DNA from embryos produced through assisted reproductive techniques.
Embryo Biopsy
PGT starts with an embryo biopsy procedure in order to obtain sample cells for embryonic DNA analysis.
Samples are Sent to PacGenomics
Your clinic then sends the samples to PacGenomics’ certified clinical genetics laboratory where PGT is performed.
PGT is Performed
PacGenomics’ laboratory performs DNA sequencing and data analysis on the sample(s) received.
Report Generated
After testing data is analyzed, PacGenomics provides a PGT report to your care team.
Embryo selection and transfer
Embryos that are most likely to lead to successful implantation are chosen for transfer.
Preimplantation Genetic Testing for Aneuploidies
Preimplantation Genetic Testing for Aneuploidies (PGT-A), formerly known as Preimplantation Genetic Screening (PGS), is a genetic test used to evaluate embryos produced through IVF for extra or missing chromosomes. Using genetic information gathered through PGT-A, your care team can select embryos that are best suited for transfer and increase your chances of successful pregnancy.
What are the benefits of PGT-A?
- Higher pregnancy rates per transfer
- Reduced risk of miscarriage
- Reducing the number of IVF cycles needed to achieve pregnancy
- Fewer implantation failures
Should I use PGT-A?
PGT-A is recommended for many people undergoing IVF treatment. All women have a chance of producing genetically abnormal embryos and this chance increases significantly as a woman ages. You may also consider PGT-A if you have experienced any of the following:
- Repeated IVF treatment failure
- Recurrent pregnancy loss
- Previous child or pregnancy with a chromosomal abnormality
Preimplantation Genetic Testing for Chromosomal Structural Rearrangements
PGT-SR is performed to screen for embryos with detectable structural chromosomal abnormalities, including unbalanced translocations and inversions.
Testing is performed on embryos produced through IVF and only embryos with no detectable abnormalities are chosen for transfer. By screening for genetic abnormalities, you can increase your chances of achieving a successful pregnancy.
Preimplantation genetic testing to distinguish between normal and balanced carrier embryos in translocation cases
- PGT-SR-Plus® can differentiate balanced translocation carrier embryos from normal embryos.
- PGT-SR-Plus® does not require patient-specific probes to be built for testing.* Therefore, the turnaround time is not affected by the unique additional information offered with this platform.
- PGT-SR-Plus® is seamlessly tailored to PacGenomics’ PGT-SR screening protocol, which has a successful record of identifying translocation carriers among patients who are not initially suspected to be at significant risk.
* Further, for most translocation screening cases at PacGenomics, an affected individual as a reference sample is not needed. Rare situations may arise (depending on the number of available embryos for testing) that prevent our team from conducting PGT-SR-Plus® testing on PGT-SR screened embryos.
Preimplantation Genetic Testing for Monogenic or Single Gene Defects
PacGenomics PGT-M is coming soon.
PGT-M is a genetic test designed for those who know they are at an increased risk of passing down a genetic disorder. PGT-M, or preimplantation genetic testing for monogenic/single gene defects was previously known as PGD, preimplantation genetic diagnosis. PGT-M is performed prior to pregnancy on embryos created through assisted reproductive techniques (ART). Only embryos without detectable monogenic disorders are then selected for transfer, greatly reducing the risk of having an affected child.